Galmed Pharmaceuticals Ltd (GLMD) — Cash Flow-to-Debt Ratio
Galmed Pharmaceuticals Ltd (GLMD) has a Cash Flow-to-Debt Ratio of -0.68x as of December 2025, meaning its operating cash flow of $-1.95 Million could theoretically repay -1% of its total liabilities ($2.85 Million) in one year. Explore Galmed Pharmaceuticals Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Galmed Pharmaceuticals Ltd Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Galmed Pharmaceuticals Ltd across 14 annual periods. Also explore GLMD total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Galmed Pharmaceuticals Ltd (2012–2025)
Year-by-year debt coverage analysis for Galmed Pharmaceuticals Ltd. For market capitalisation and broader financial context, see Galmed Pharmaceuticals Ltd (GLMD) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.22x | $-6.32 Million | $2.85 Million | ▲ +18.0% |
| 2024 | -2.71x | $-5.88 Million | $2.17 Million | ▼ -21.3% |
| 2023 | -2.23x | $-6.14 Million | $2.75 Million | ▲ +62.1% |
| 2022 | -5.90x | $-18.50 Million | $3.14 Million | ▼ -9.5% |
| 2021 | -5.39x | $-32.89 Million | $6.11 Million | ▼ -68.6% |
| 2020 | -3.19x | $-26.29 Million | $8.23 Million | ▼ -55.8% |
| 2019 | -2.05x | $-14.94 Million | $7.29 Million | ▲ +38.5% |
| 2018 | -3.33x | $-9.02 Million | $2.71 Million | ▼ -6.3% |
| 2017 | -3.14x | $-12.07 Million | $3.85 Million | ▼ -39.0% |
| 2016 | -2.26x | $-12.13 Million | $5.38 Million | ▲ +27.6% |
| 2015 | -3.12x | $-8.47 Million | $2.72 Million | ▲ +48.8% |
| 2014 | -6.09x | $-9.24 Million | $1.52 Million | ▼ -410.6% |
| 2013 | -1.19x | $-2.52 Million | $2.12 Million | ▼ -6.1% |
| 2012 | -1.12x | $-3.08 Million | $2.74 Million | — |